Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 10: ONTARGET - Rationale Abb. 11: ONTARGET - rationale Abb. 12: ONTARGET - rationale Aktuelles Bild - Abb. 13: ONTARGET - objectives Abb. 14: ONTARGET - a global trial Abb. 15: ONTARGET - participating countries Abb. 16: ONTARGET will be the largest ARB trial to date Zum letzten Bild
Abbildung 13: ONTARGET - objectives
Despite the sound rationale for combining an ARB with an ACE inhibitor, there are currently only two other large-scale trials that will include analyses to examine the efficacy of an ARB vs an ACE inhibitor and their combination. These are the Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM), [8] and the Valsartan In Acute Myocardial Infarction Trial (VALIANT). [9] ONTARGET will investigate the efficacy of telmisartan monotherapy compared with ramipril monotherapy in preventing cardiovascular morbidity and mortality in a high-risk population. ONTARGET will determine any additional benefit of combining telmisartan with ramipril, compared with the ACE inhibitor alone. 8. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-282. 9. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design Am Heart J 2000;140:727-734.
 
ONTARGET - objectives
Vorheriges Bild Nächstes Bild   


Abbildung 13: ONTARGET - objectives
Despite the sound rationale for combining an ARB with an ACE inhibitor, there are currently only two other large-scale trials that will include analyses to examine the efficacy of an ARB vs an ACE inhibitor and their combination. These are the Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM), [8] and the Valsartan In Acute Myocardial Infarction Trial (VALIANT). [9] ONTARGET will investigate the efficacy of telmisartan monotherapy compared with ramipril monotherapy in preventing cardiovascular morbidity and mortality in a high-risk population. ONTARGET will determine any additional benefit of combining telmisartan with ramipril, compared with the ACE inhibitor alone. 8. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-282. 9. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design Am Heart J 2000;140:727-734.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung